SABCS 2022 | Window of opportunity ELIPSE trial: elacestrant in postmenopausal women with ER+HER2-/ early BC

Maria Jesús Vidal, MD, PhD, Hospital Clinic of Barcelona, Barcelona, Spain, provides an overview of the early Phase I SOLTI-1905-ELIPSE (NCT04797728) trial, a window-of-opportunity trial investigating elacestrant in a preoperative setting in postmenopausal woman with ER-positive and HER2-negative breast cancer amenable to surgery. The primary endpoint was the complete cell-cycle arrest after 4 weeks of elacestrant therapy. Overall, elacestrant was associated with a shift towards a more endocrine sensitive and less proliferative phenotype based on PAM50 gene signatures. An increase in luminal genes and decrease in proliferative genes was observed. A switch between Luminal A to Luminal B tumors was observed in 67% of patients. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.